Amgen rejigs Bay Area presence with deal for new R&D facility

Amgen's Gateway of Pacific building in South San Francisco (Business Wire)

Amgen has signed a lease on a 240,000-square-foot facility in South San Francisco, positioning it to join AbbVie in a new campus. The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

Today, Amgen leases seven buildings covering 684,000 square feet in the Bay Area, although some of this space is subleased to third parties. With those leases due to end between December 2021 and December 2023, Amgen has put in place new deals to secure its future in the Bay Area, modifying the terms of its current arrangement while forming an agreement with BioMed Realty for new space. 

The BioMed Realty deal will give Amgen a long-term lease on 240,000 square feet of space that is under construction at the Gateway of Pacific campus at Oyster Point. Amgen expects to move its Bay Area cardiometabolic, inflammation and oncology researchers into the digs in 2022. The scientists will work out of a site that has “modular green wet labs and green molecular lab design.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Amgen is the second big biopharma company to commit to the Gateway of Pacific campus. AbbVie snapped up 94% of the 509,000 square feet of space BioMed Realty is creating in the first phase of the project. Amgen’s 240,000-square-foot facility will take up the north tower of the second phase of the project, which will provide 440,000 square feet of space in total. Construction of a third phase of the project, which will add a further 350,000 square feet of space, began recently. 

In conjunction with the deal for new space, Amgen has revised the terms of its existing leases with Healthpeak Properties. The lease on three buildings on Veterans Boulevard, which was due to expire in two years, is now due to run until the end of 2029. However, Amgen can terminate the lease on the 257,000 square feet of space in two tranches in 2022 and 2024. 

“With this amendment, Amgen retains flexible rights to continued occupancy at several important research and development facilities, while providing Healthpeak the clarity needed to advance discussions with prospective tenants looking for space at this irreplaceable campus,” Healthpeak Chief Financial Officer Pete Scott said in a statement.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.